Neural stem cells (NSCs) give rise to all the major cell types in the brain, including neurons, oligodendrocytes, and astrocytes. However, the intracellular signaling pathways that govern brain NSC proliferation and differentiation have been incompletely characterized to date. Since some neurodevelopmental brain disorders (Costello syndrome and Noonan syndrome) are caused by germline activating mutations in the RAS genes, Ras small GTPases are likely critical regulators of brain NSC function. In the mammalian brain, Ras exists as three distinct molecules (H-Ras, KRas, and N-Ras), each with different subcellular localizations, downstream signaling effectors, and biological effects. Leveraging a novel series of conditional-activated Ras moleculeexpressing genetically engineered mouse strains, we demonstrate that activated K-Ras, but not H-Ras or N-Ras, expression increases brain NSC growth in a Raf-dependent, but Mekindependent, manner. Moreover, we show that activated K-Ras regulation of brain NSC proliferation requires Raf binding and suppression of retinoblastoma (Rb) function. Collectively, these observations establish tissue-specific differences in activated Ras molecule regulation of brain cell growth that operate through a noncanonical mechanism.
INTRODUCTION
Neural stem cells (NSCs) represent a selfrenewing population found in neurogenic regions of the embryonic and adult brain [1, 2] . In addition to forming new NSCs (selfrenewal and proliferation), these stem cells can also give rise to all the major cell types in the brain, including neurons, oligodendrocytes, and astrocytes, through multilineage differentiation [3] [4] [5] [6] . Each of these cell fate decisions requires the activation of signaling pathways and transcriptional programs [3, [7] [8] [9] [10] [11] . In this regard, numerous potential regulatory mechanisms, involving p53, Bmi1, sonic hedgehog, Notch, p27, REST/NSRF, epidermal growth factor receptor, and others [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] , have been reported. While many of these signaling molecules are responsible for NSC growth and differentiation, it is not clear which ones are important for the pathogenesis of diseases characterized by abnormal brain NSC function.
A number of neurodevelopmental disorders, including neurofibromatosis type 1, Costello syndrome, and Noonan syndrome, are caused by mutational activation of the Ras proto-oncogene [24] [25] [26] [27] . Specifically, some individuals with Noonan syndrome (OMIM 218040; 613224) harbor germline activating mutations in the K-RAS or N-RAS genes, while activating H-RAS mutations have been reported in individuals affected with Costello syndrome (OMIM 613224). Normally, small GTPase proteins, like Ras, act as molecular switches by alternating between active, GTPbound and inactive, GDP-bound states [28] . However, in Costello and Noonan syndrome, these germline mutations result in Ras proteins, which are locked in the active GTPbound form, leading to unchecked Ras pathway hyperactivation.
Ras exists as three separate molecules (HRas, K-Ras, and N-Ras). Despite 85% amino acid sequence similarity, the specific functions of each Ras molecule are dictated by distinct C-terminal 25-amino acid residues within the unique hypervariable regions (HVRs). While these HVRs contain CAAX-box motifs which are isoprenylated to allow for Ras targeting to the plasma membrane (PM) [29] , differential palmitoylation directs their trafficking to the PM via the Golgi (H-Ras, N-Ras) or other, unknown mechanisms (K-Ras) [30, 31] . This differential processing directs the Ras molecules to distinct domains within the PM [32] , and is thought to underlie their differential capacities to signal to downstream effector proteins in different cellular contexts [29, 33, 34] .
Based on these potential differences, we hypothesized that activated H-Ras, K-Ras, and N-Ras expression, as observed in the Noonan and Costello neurogenetic disorders, may differentially regulate NSC growth and differentiation. Using a combination of in vivo and in vitro approaches, we demonstrate that controlled expression of activated K-Ras, but not H-Ras or N-Ras, increases brain NSC proliferation without altering multilineage differentiation. Moreover, activated K-Ras controls brain NSC growth in a Raf-dependent, but Mek-independent manner, through binding and inhibition of retinoblastoma protein (Rb) function.
MATERIALS AND METHODS

Mice
Activated H-Ras, K-Ras, or N-Ras allele expression were induced in NSCs in vivo by intercrossing BLBP-Cre [35] mice with mice containing Lox-Stop-Lox (LSL)-H-Ras G12V (Supporting Information Fig. S1 ; generated by Dr. Kevin Haigis), LSL-KRas G12D [36] , or LSL-N-Ras G12D [37] constructs knocked into the respective Ras locus. All mice were maintained on a C57Bl/6 background in accordance with approved animal studies protocols at Washington University.
Immunohistochemistry
Brain tissues were collected at postnatal day 18 (PN18). Prior to tissue harvesting, mice were intracardially perfused with Ringer's solution containing lidocaine and heparin followed by 4% paraformaldehyde. Tissues were postfixed overnight in 4% paraformaldehyde and then in 70% ethanol overnight before embedding. Paraffin-embedded tissues were sectioned at 6 lm thickness using a Leica RM2125 RTS microtome (Leica Microsystems, Inc., Buffalo Grove, IL, www.leica-microsystems. com). Antigen retrieval and appropriate primary antibodies (Supporting Information Table S1 ) were applied overnight at 4 C in immunohistochemistry (IHC) diluent (1% milk, 2% bovine serum albumin (BSA), and 2% goat serum in tris-buffered saline (TBS)-Tween). Tissues were then incubated with speciesappropriate horseradish peroxidase-conjugated secondary antibodies (Vector Laboratories, Burlingame, CA, www.vectorlabs. com) in IHC diluent. Photomicrographs of the pons (Supporting Information Fig. S2 ) were acquired on a Nikon Eclipse E600 light microscope (Nikon Instruments, Inc., Melville, NY, www. nikoninstruments.com) equipped with a Leica EC3 camera (Leica Microsystems). Six to ten mice were collected per genotype along with appropriate matched littermate controls.
Immunofluorescence
Brain tissues were collected as described above. Following fixation, the brains were dehydrated in 30% sucrose for 24 hours prior to embedding in OCT mounting media (Sakura Finetek, Torrance, CA, www.sakura-americas.com) and freezing at 280 C. Frozen tissues were cut into 10-lm-thick sections on a Reichert-Jung Cryocut 1800 cryostat (Reichert Technologies, Depew, NY, www.reichert.com). Primary antibodies (Supporting Information Table S1 ) were applied overnight at 4 C in immunofluorescence (IF) diluent (2% BSA, 2% goat serum in TBS-Tween). Tissues were subsequently incubated with species-appropriate AlexaFluor 488 or 568 secondary antibodies (Life Technologies, Grand Island, NY, www.lifetechnologies. com) in IF diluent. Nuclei were counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI) for cell counting. Images of the pons were acquired using a Nikon Eclipse TE300 inverted fluorescent microscope equipped with a Photometrics CoolSnap EZ camera (Photometrics, Tucson, AZ, www.photometrics. com). Images of the embryonic hindbrain (site of the future pons) were acquired using a Leica DFC 3000G camera (Leica Microsystems). Lineage antibody-positive cells were normalized to the total tissue surface areas within the images, and quantified using Leica Application Suite Advanced Fluorescence software (Leica Microsystems).
NSC Culture
NSCs were generated from PN1 brainstems, as previously reported [38] . 
NSC Growth
NSC growth was assessed by direct cell counting following the seeding of 5,000 NSCs (in triplicate) in 24-well ultra-low attachment dishes (Corning) containing NSC media. Cells were trypsinized and counted using a hemocytometer after 5 days in culture. Each experiment was repeated at least three times using NSCs harvested from three independently generated litters. For the immunocytochemistry experiments, neurospheres were collected after 5 days in culture, washed twice in phosphate-buffered saline (PBS), and fixed for 30 minutes in 4% paraformaldehyde. Neurospheres were then dehydrated in 30% sucrose for at least 24 hours prior to embedding in OCT mounting media (Sakura Finetek) and freezing at 280 C. All frozen embedded neurospheres were cut into 10-lm-thick sections on a Reichert-Jung Cryocut 1800 cryostat (Reichert Technologies, Depew, NY). Primary antibodies (Supporting Information Table  S1 ) were applied overnight at 4 C in IF diluent. Tissues were subsequently incubated with species-appropriate AlexaFluor 488 or 568 secondary antibodies (Life Technologies) in IF diluent and counterstained with DAPI. At least eight neurospheres of similar diameter and cell number were imaged per sample and compared to LacZ-infected control cells.
In Vitro NSC Differentiation
Differentiation was assessed by seeding 150,000 NSCs in triplicate onto 24-well plates coated with 50 lg/ml poly(D-lysine) (Sigma-Aldrich) and 10 lg/ml fibronectin (Life Technologies) in NSC media supplemented with 1% N2, 2% B27, and 1% fetal bovine serum. After 6 days in culture, adherent cells were fixed for 15 minutes in 4% paraformaldehyde and stained 0 -deoxyuridine (EdU; Life Technologies) was added to the culture media 3 hours prior to fixation. EdU was detected using the Click-IT EdU Assay Kit (Life Technologies) prior to immunocytochemistry staining according to manufacturer's protocol. Each experiment was repeated at least three times using NSCs harvested from three independently generated litters.
Flow Cytometry Analysis
Neurospheres were trypsinized and fixed overnight in 50% ethanol in PBS containing 0.02% IGEPAL (Sigma-Aldrich 
Western Blotting
NSCs were incubated in NSC media without B27, N2, EGF, and FGF growth supplements for 2 hours prior to a brief PBS wash and centrifugation. Cell pellets were lysed in cold lysis buffer (20 mM Tris [pH 7.5], 10 mM EGTA, 40 mM bglycerophosphate, 1% Nonidet P40, 2.5 mM MgCl 2 , and 2 mM sodium orthovanadate) supplemented with aprotinin (1.4 lg/ ml), leupeptin (1 lg/ml), and phenylmethanesulfonylfluoride (1 mM) protease inhibitors for protein quantitation using the Pierce BCA Protein Assay Kit (Thermo Fisher, Waltham, MA, www.thermofisher.com). The resulting cell lysates (20 lg) were separated by SDS-PAGE followed by transfer to polyvinylidene difluoride membranes (Immobilon, Thermo Fisher). Membranes were blocked with 5% milk in 13 TBS-Tween prior to overnight incubation at 4 C with appropriate primary antibodies (Supporting Information Table S2 ). Detection was achieved using species-appropriate HRP-linked secondary antibodies (Cell Signaling, Danvers, MA, www.cellsignal.com) and enhanced chemiluminescence imaging (Bio-Rad Laboratories, Hercules, CA, www.bio-rad.com) using the ChemiDoc-It Imaging System (UVP, Upland, CA, www.uvp.com).
Pharmacological Inhibition Studies
The minimum effective inhibitor drug concentrations required to reduce K-Ras* NSC signaling activity to the levels observed in control NSCs were empirically determined by dose escalation experiments (data not shown). Using these doses, NSCs were treated with either 6.5 lM GGTI-286 (Millipore), 200 nM AZ628 (Selleck Chemicals, Houston, TX, www.selleckchem.com), 2 nM PD0325901 (Selleck Chemicals), 50 nM MEK162 (Selleck Chemicals), 50 nM AZD0530 (Selleck Chemicals), 20 lM SB203580 (Selleck Chemicals), or 5 lM RRD-251 (Sigma-Aldrich) for 5 days in culture. DMSO treatment served as a vehicle control.
Dominant-Negative K-Ras Inhibition
Dominant-negative K-Ras (dnK-Ras N17 ) in the MSCV retroviral plasmid vector p5Ra-IRES-GFP [39] was used to generate virus in human embryonic kidney 293T cells. MSCV-IRES-GFP served as control virus. Successful infection was confirmed by green fluorescent protein (GFP) expression in both control and dnKRas N17 -infected NSCs (Fig. 6C , Supporting Information Fig. S5B ).
Immunoprecipitation
Raf-1 immunoprecipitation was performed using whole cell lysates in binding buffer containing 20 mM HEPES (pH 7.9), 40 mM KCl, 1 mM MgCl 2 , 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM dithiothreitol, 0.1 NaF, 0.1 mM Na 3 VO 4 , 0.5% IGEPAL, and 3 mg/ml BSA. Total protein (500 lg) in 400 ll of binding buffer was precleared with 30 ll agarose protein G beads (Cell Signaling) for 2 hours at 4 C on a rotor. After removing the beads, lysates were incubated with Raf-1 monoclonal antibodies (Millipore, Supporting Information Table S1 ) overnight at 4 C on a rotor. Following the addition of agarose beads for an additional 2 hours, the beads were washed three times in 500 ll binding buffer, boiled in 20 ll 43 Laemmli buffer (Bio-Rad Laboratories), and separated on 8% polyacrylamide gels for Western blotting. Raf-1 pull-down was confirmed by blotting with a different Raf-1 antibody (Cell Signaling, Supporting Information Table S2 ).
Data Analysis
Tissue and cell staining images were quantitated using ImageJ version 10.2 image analysis software (National Institutes of Health, http://imagej.nih.gov/ij/). The Grubbs outlier test was used to determine statistical outliers, and statistical significance (*, p < .05; **, p < .01; ***, p < .001) determined using an unpaired, two-tailed Student's t test and GraphPad Prism 5 software (Graph-Pad Software, La Jolla, CA, www.graphpad.com).
RESULTS
Activated NSC K-Ras Expression Leads to Increased Astrogliogenesis In Vivo
To define the impact of activated Ras expression on NSC function in vivo, we leveraged BLBP-Cre mice to target-activated Ras molecule expression to brain ventricular zone NSCs capable of giving rise to neurons, oligodendrocytes, and astrocytes in vivo (multilineage differentiation) [35] . This specific Cre driver strain was chosen, since Ras activation in nestin 1 cells (nestin-Cre mice) is likely to result in embryonic lethality due to a defect in cardiac vessel septation [40] . Moreover, we have previously used this particular BLBP-Cre strain to examine the impact of neurofibromatosis-1 loss on gliogenesis in vivo [35] . 
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The expression of each individual-activated Ras allele was accomplished using mice in which an oncogenic version was knocked into the endogenous Ras locus. Specifically, these Ras LSL (H-Ras
, or N-Ras LSL-G12D ) mice contain a transcriptional stop element flanked by LoxP sites (LoxStop-Lox [LSL] ) that prevents expression of the mutationally activated Ras alleles in the absence of Cre expression. Following Cre-mediated recombination, mutationally activated Ras (Ras*) is expressed from its endogenous promoter.
Since the majority of neuronal and non-neuronal cell fate specification occurs by 3 weeks following birth, we examined the consequence of activated Ras molecule expression on brain cell development at postnatal day 18 (PN18). At PN18, there was a greater percentage of astrocytes in K-Ras* BLBP , but not H-Ras* BLBP or N-Ras* BLBP , mice relative to littermate controls using glial fibrillary acidic protein (GFAP) (1.8-fold) and S100b (1.2-fold) astrocyte antibodies (Fig. 1A, 1B) . In contrast, there was no change in APC 1 oligodendrocytes (Fig. 1C) or NeuN 1 neurons (Fig. 1D ) or differences in brain or body weights across the three Ras genotypes relative to controls (Supporting Information Fig. S3 ). These data demonstrate that activated K-Ras, but not H-Ras or N-Ras, expression in NSCs leads to the generation of more astrocytes in vivo. Activated K-Ras Expression Does Not Alter NSC Astrocyte Differentiation
To determine whether activated K-Ras expression alters brain NSC astrocyte differentiation, we used neurosphere cultures generated from brainstems of PN1 pups infected with adenovirus expressing either LacZ (control cells, CTL) or Cre recombinase (activated H-Ras, K-Ras, or N-Ras, denoted H-Ras*, K-Ras*, or NRas*, respectively). Raf1-RBD affinity chromatography confirmed that Ras activation was comparably increased after Ad5-Cre infection ( Fig. 2A) . Following in vitro differentiation of these NSCs for more than 6 days in adherent culture, only K-Ras*-expressing NSCs exhibited increased numbers of GFAP 1 astrocytes (1.8-fold) relative to controls (Fig. 2B) . Importantly, K-Ras*-expressing NSC cultures also showed an increase in the total number of DAPI 1 cells (1.8-fold) compared to control cells (Fig. 2C) . The increase in GFAP 1 cells proportional to total DAPI 1 cells resulted in no change in the percentage of GFAP 1 cells compared to controls (Fig. 2D) , indicating that activated K-Ras expression does not directly change NSC astrocyte differentiation.
To determine whether the increase in astrocyte numbers following K-Ras* expression reflected an increase in the NSC pool during differentiation (EdU incorporation), we examined differentiating cells at both early (1 day postplating) and late (5 days postplating) time points (Fig. 3A) . In addition to EdU incorporation, neuroglial lineage antibodies for NSCs (Sox2) and astrocytes (GFAP) were used to quantify changes in both populations. After 1 day in culture, K-Ras*-expressing cells were proliferating 7.4-fold more than their control counterparts (Fig. 3B) . These proliferating cells were exclusively Sox2 1 NSCs, and not GFAP 1 astrocytes (Fig. 3C) . At this time, there was no change in the percentage of Sox2 1 NSCs; however, a smaller percentage of K-Ras*-expressing cells were GFAP 1 astrocytes relative to control cells (Fig. 3D) . After 5 days in culture, K-Ras*-expressing cells were still proliferating 2.2-fold more than controls (Fig. 3E) ; however, there was no difference in proliferating NSCs or astrocytes (Fig. 3F) . While a higher percentage (1.6-fold) of K-Ras*-expressing cells were Sox2
1 NSCs relative to control cells, there was no difference in the percentage of GFAP 1 astrocytes in either K-Ras* or control cell populations (Fig. 3G) . Together, these data demonstrate that activated K-Ras expression increases the NSC pool, rather than driving NSCs toward astrocyte differentiation.
Activated K-Ras Expression Increases NSC Proliferation In Vitro
To determine whether the individual Ras* molecules differentially increase NSC growth in vitro, we directly counted NSCs after 5 days in culture. Similar to the above findings, 2.3-fold more K-Ras*-, but not H-Ras*-or N-Ras*-, expressing NSCs were observed relative to controls (Fig. 4A) . At this time, KRas*-, but not H-Ras*-or N-Ras*-, expressing neurospheres had a 1.6-fold increase in the percentage of Ki67 1 proliferating cells (Fig. 4B) . Following continued in vitro passage, this KRas*-expressing NSC growth advantage was sustained for approximately five passages, after which, both control and KRas*-expressing NSCs failed to survive (Supporting Information  Fig. S4 ). To determine whether the increased K-Ras* NSC growth reflected increased proliferation or decreased cell death, flow cytometry was used. Using propidium iodide to analyze cellular DNA content, fewer K-Ras*-expressing NSCs were in the precycling G 0 /G 1 phase (24.6%) of the cell cycle relative to controls, while more K-Ras*-expressing NSCs were in S phase (13.6%) and G 2 /M phase (12.6%) (Fig. 4C,  4D ). Finally, using annexin-V staining to identify cells undergoing programmed cell death (apoptosis), no differences were found between live and apoptotic K-Ras*-expressing and control NSCs (Fig. 4E, 4F) . Collectively, these data are consistent with a model in which activated K-Ras expression increases NSC proliferation to expand the NSC pool and result in a proportional increase in astrocytes following differentiation (Fig. 4G) (Fig. 5A) . At PN1, no difference in the numbers of Sox2
1 NSCs was observed in the brainstems of K-Ras* BLBP versus littermate control mice (Fig. 5B) . However, at PN1, there was a 1.9-fold increase in the numbers of Olig2 1 glial-restricted progenitor cells following activated K-Ras expression (Fig. 5C) . Together, these data demonstrate that activated K-Ras expression in NSCs results in an early expansion of progenitor cells, which likely underlies the increase in astrocytes observed in the K-Ras* BLBP mouse brainstem at PN18.
Activated K-Ras Expression Increases NSC Proliferation in a Raf-Dependent, but Mek-Independent, Manner
Using a Raf-RBD affinity assay, K-Ras activation activity was 30-fold higher in K-Ras*-expressing NSCs relative to controls (Fig. 6A) . Based on this level of K-Ras activation, pharmacological inhibitor studies were used to define the downstream signaling pathway responsible for activated K-Ras (K-Ras*) control of NSC proliferation. We experimentally defined the minimal doses of pharmacological inhibitors required to reduce K-Ras* effector pathway hyperactivation to WT control levels (data not shown). First, we confirmed that K-Ras activation was required for K-Ras*-induced NSC hyperproliferation using the GGTI-286 geranylgeranyltransferase inhibitor. Following GGTI-286 (6.5 lM) treatment, the hyperproliferation of KRas* NSCs was reduced to that of control cells, as measured by direct cell counting (Fig. 6B, Supporting Information Fig.  S5A ). Western blot analysis of the Ras downstream effector protein Erk revealed reduced p-Erk activity following GGTI-286 inhibition. Similarly, infection of K-Ras* NSCs with dominantnegative K-Ras (dnK-Ras N17 ; [39] ) reduced K-Ras* NSC hyperproliferation to that of control cells, as measured by direct cell counting (Fig. 6C, Supporting Information Fig. S5B ).
Second, after inhibition with the pan-Raf inhibitor AZ628 (200 nM), K-Ras*-induced NSC hyperproliferation was attenuated to that of control cells (Fig. 6D , Supporting Information Fig. S5C ). As previously reported, increased Erk activation was observed following Raf inhibitor treatment [41] , thus precluding independent confirmation of AZ628 Raf inhibition. Consistent with Ras-and Raf-mediated activation, increased Erk activation was observed in K-Ras*-expressing NSCs (Fig. 6E) .
Third, to determine whether Raf/Mek signaling was responsible for K-Ras*-induced NSC hyperproliferation, K-Ras*-expressing NSCs were treated with the PD0325901 (PD901; 2 nM) or MEK162 (50 nM) Mek inhibitors. Treatment with either PD901 or MEK162 reduced Erk hyperactivation, but did not attenuate K-Ras*-mediated NSC hyperproliferation (Fig.  6F, 6G, Supporting Information Fig. S5D, S5E ).
These unexpected results prompted a detailed examination of other potential Raf effector proteins. While we observed no change in Akt, Jnk, PKC-c, PKC-f, Ran, b-catenin, and Yap activity, Src and p38MAPK were hyperactivated (increased Src Y416 and p38MAPK T180/Y182 phosphorylation, respectively) in K-Ras*-expressing NSCs compared to controls (Supporting Information  Fig. S6A, S6B) . However, pharmacologic inhibition of Src (50 nM AZD0530) or p38MAPK (20 lM SB203580) activity did not reduce K-Ras*-induced NSC hyperproliferation (Supporting Information Fig. S6C, S6D) . Similarly, neither GGTI-286 (Ras inhibitor) nor AZ628 (Raf inhibitor) treatments reduced Src or p38MAPK hyperactivation (Supporting Information Fig. S6E ).
Collectively, these data demonstrate that K-Ras* expression increases NSC proliferation in a Raf-dependent, but Mek-, Src-, and p38MAPK-independent, manner.
Raf-1 Inhibition of Rb Is Responsible for Activated K-Ras-Induced NSC Hyperproliferation
To determine how K-Ras* regulates NSC proliferation, we focused on potential Raf-dependent mechanisms. Previous studies have shown that Raf-1 (c-Raf) directly binds the retinoblastoma tumor suppressor protein (Rb) to relieve Rb- STEM CELLS mediated suppression of cell cycle progression [42] . We found that endogenous Rb bound to Raf-1 in K-Ras*-expressing NSCs, as assessed by Raf-1 immunoprecipitation (Fig. 7A) . Based on these findings, we used a small peptide inhibitor, RRD-251, previously shown to disrupt the Raf-1/Rb interaction [43, 44] , to demonstrate that this particular interaction was required for K-Ras*-mediated NSC hyperproliferation. Treatment of K-Ras*-expressing NSCs with RRD-251 (5 lM) reduced K-Ras*-induced NSC hyperproliferation to control levels (Fig. 7B, Supporting Information Fig. S7 ). Together, these (Fig. 7C) .
DISCUSSION
Despite the central role of Ras in regulating embryonic development, the three Ras molecules do not equally impact on this process. For example, biallelic K-Ras deletion in mice results in lethality between 12 and 14 days of gestation, due to brainstem defects, hematopoietic abnormalities, and organ failure [45, 46] . In contrast, H-Ras or N-Ras deletion, either separately or in combination, does not impair normal embryonic development, resulting in healthy adult mice [47, 48] . These differential effects are further highlighted by observations made in human neurogenetic disorders characterized by germline activating mutations in the three RAS genes (collectively termed "RASopathies"). In these RASopathies, H-RAS mutations [26] have been reported in Costello syndrome, whereas individuals with Noonan syndrome harbor K-RAS mutations [27] , each with varying neurocognitive delays and learning disabilities. The importance of differential Ras molecule activation is additionally underscored by the finding of oncogenic K-RAS, but not H-RAS or N-RAS, mutations in pediatric brain tumors [49, 50] . Herein, we demonstrate that activated K-Ras, but not HRas or N-Ras, molecule expression increases the proliferation of brain NSCs. While no prior studies have systematically compared the consequences of expressing these three individualactivated Ras molecules in the brain, previous work in other tissue types has revealed divergent functions for each of these proteins. In neural crest-derived hematopoietic cells, activated N-Ras is the primary regulator of cell self-renewal, 
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proliferation, and cell fate decisions [51] [52] [53] [54] , whereas activated K-Ras primarily drives cell growth in endoderm-derived tissues (lungs and colon) [36, 55] . Similarly, in endodermderived stem cells, overexpression of active H-Ras G12V promotes cell differentiation and suppresses cell growth, in contrast to K-Ras G12V overexpression that promotes stem cell proliferation and inhibits cell differentiation [56] . Moreover, KRas G12D expression increases the proliferation of an intestinal stem cell population, whereas N-Ras G12D expression increases the resistance of these cells to apoptosis without changing cell proliferation [37] . Lastly, K-Ras G12D expression has also been reported to cause bronchioalveolar stem cell hyperproliferation in the lung [55] . Taken together, these studies identify K-Ras* as a potent driver of progenitor cell proliferation, which is consistent with our finding that only activated K-Ras expression promotes brain NSC proliferation.
Deregulated RAS signaling is an important step in cancer initiation, with activating RAS mutations implicated in 30% of all cancers [57] . Of particular relevance to this study is the prevalence of activating K-RAS gene mutations (22% of all cancers) relative to mutations in either the H-RAS or N-RAS genes (11% of all cancers combined). Although our study focused on the developmental implications of activated Ras expression on NSC function, the increased NSC proliferation observed following K-Ras* expression prompted us to examine mice for tumor formation. In a small number of K-Ras* BLBP mice (n 5 3) aged to 8 weeks of age, all developed squamous cell papillomas of the vagina/anus. Complete necropsy did not reveal any pathology indicative of a brain tumor (data not shown). These findings are consistent with previous reports demonstrating that oncogenic Ras expression leads to increased proliferation without subsequent tumor formation. In these studies, expression of the same K-Ras LSL allele in colonic epithelial cells resulted in hyperplasia, but not neoplasia, of the intestinal epithelium [37] . It was only when K-Ras* expression was combined with loss of Apc expression did colonic tumors form. Similarly, KRas* expression alone in nestin 1 or GFAP 1 neural stem/progenitor cells in the brain was not sufficient for tumor formation [51, 58] , yet led to glioblastoma when combined with constitutively active Akt expression [59] . Given the high level of sequence similarity between the three Ras molecules and their capacity to signal to a similar subset of downstream effector proteins, it is striking that these molecules have such divergent functions. However, these differences are conferred by unique 25-amino acid, Cterminal HVRs. During post-translational processing, the Ras molecules are first prenylated by farnesyltransferase, which allows for trafficking to the endoplasmic reticulum [60, 61] . After this step, Ras molecule post-translational processing diverges: K-Ras becomes more highly methylated than its HRas and N-Ras counterparts [30] . H-Ras and N-Ras are then palmitoylated and trafficked to the PM through the Golgi apparatus while methylated K-Ras is trafficked to the PM independent of the Golgi [31, 58] . The exact mechanism responsible for mediating K-Ras trafficking is unknown; however, its transport has been shown to be dependent on a polybasic, lysine-rich portion of the K-Ras HVR not found within the HVRs of H-Ras or N-Ras [62] . Following its PM localization, each Ras molecule occupies a different microdomain: N-Ras is found in lipid raft domains, while K-Ras localizes to non-lipid raft portions of the membrane [32, 63] . H-Ras occupies lipid raft domains when inactive, but translocates to non-lipid raft membrane upon activation (in areas distinct from those occupied by K-Ras) [32, 64] . In addition, H-Ras and N-Ras are also capable of signaling to downstream effectors from the Golgi, a capability not shared by K-Ras [65, 66] . Collectively, the divergent processing and localization of the Ras molecules likely account for their capacities to signal to different subsets of downstream proteins to generate different biological outcomes [33, 34] .
Ras/Raf signal transduction most commonly operates through Raf activation of Mek1/2 [67] [68] [69] . In striking contrast to this canonical signaling mechanism, we demonstrate that activated K-Ras expression increases brain NSC proliferation in a Raf-dependent manner that operates independent of Mek. Precedent for Mek-independent Ras/Raf growth control derives from several studies performed in numerous different cell types. First, Raf-1 overexpression has been shown to increase cell survival by inhibiting ASK-1 function in the presence of the Mek pharmacological inhibitors PD98059 and U0126 [70] . Second, K-Ras*-expressing DLD-1 cells continue to proliferate despite treatment with the Mek inhibitor CI-1040. Proliferation of these cells was only inhibited in the presence of the Raf inhibitor AZ628 [37] . Third, protein binding discovery studies have revealed several other potential Raf binding partners, including the 14-3-3-zeta protein, which modulates Raf signaling during cell stress through its association with keratin 8/18 [71, 72] . Fourth, both B-Raf and Raf-1 associate with PKC-theta to inactivate the proapoptotic Bcl-2 family protein BAD and increase cell survival [73] . While these studies collectively identify a role for Raf in cell growth, we found that K-Ras*-dependent brain NSC hyperproliferation depends on the productive interaction between Raf-1 and the retinoblastoma (Rb) cell cycle regulator [42] .
The Rb tumor suppressor protein prevents cell cycle progression by inhibiting the expression of the E2F transcription factors to prevent DNA synthesis. Upon growth factor stimulation, this inhibition is relieved, allowing cells to progress through the cell cycle. Using genetic and biochemical techniques to alter Ras expression in the presence or absence of Rb expression, early work established a hierarchy for Ras/Rb/cell cycle regulation, whereby Ras inhibition of Rb function led to increased proliferation [74, 75] . The mechanism underlying this Ras/Rb connection was identified when direct binding between Raf-1 and Rb was revealed [42] . Consistent with previous studies demonstrating that the RRD-251 small peptide interrupts this interaction and block tumor cell growth [42] [43] [44] [76] [77] [78] , we found that K-Ras*-induced NSC hyperproliferation depended on Raf/Rb binding and inhibition of Rb function.
In summary, using a novel collection of conditional Ras genetically engineered mouse strains and derivative NSCs, we establish differential effects of the three activated Ras molecules on brain NSC proliferation. Moreover, the elucidation of a nonconventional mechanism underlying Ras/Raf-mediated NSC growth control suggests additional determinants relevant to the study of diseases characterized by deregulated RAS function. Future studies characterizing differences in Ras molecule function in disease-pertinent models will be critical to further defining and ultimately treating these disorders.
CONCLUSIONS
To our knowledge, this is the first study to compare the impact of regulated expression of all three activated Ras alleles on brain NSC function using identically constructed genetically engineered mouse strains. Using this approach, activated K-Ras, but not H-Ras or N-Ras, expression increases 
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